Cargando…

Mitochondria: a new therapeutic target in chronic kidney disease

Cellular metabolic changes during chronic kidney disease (CKD) may induce higher production of oxygen radicals that play a significant role in the progression of renal damage and in the onset of important comorbidities. This condition seems to be in part related to dysfunctional mitochondria that ca...

Descripción completa

Detalles Bibliográficos
Autores principales: Granata, Simona, Dalla Gassa, Alessandra, Tomei, Paola, Lupo, Antonio, Zaza, Gianluigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4660721/
https://www.ncbi.nlm.nih.gov/pubmed/26612997
http://dx.doi.org/10.1186/s12986-015-0044-z
_version_ 1782402858857005056
author Granata, Simona
Dalla Gassa, Alessandra
Tomei, Paola
Lupo, Antonio
Zaza, Gianluigi
author_facet Granata, Simona
Dalla Gassa, Alessandra
Tomei, Paola
Lupo, Antonio
Zaza, Gianluigi
author_sort Granata, Simona
collection PubMed
description Cellular metabolic changes during chronic kidney disease (CKD) may induce higher production of oxygen radicals that play a significant role in the progression of renal damage and in the onset of important comorbidities. This condition seems to be in part related to dysfunctional mitochondria that cause an increased electron “leakage” from the respiratory chain during oxidative phosphorylation with a consequent generation of reactive oxygen species (ROS). ROS are highly active molecules that may oxidize proteins, lipids and nucleic acids with a consequent damage of cells and tissues. To mitigate this mitochondria-related functional impairment, a variety of agents (including endogenous and food derived antioxidants, natural plants extracts, mitochondria-targeted molecules) combined with conventional therapies could be employed. However, although the anti-oxidant properties of these substances are well known, their use in clinical practice has been only partially investigated. Additionally, for their correct utilization is extremely important to understand their effects, to identify the correct target of intervention and to minimize adverse effects. Therefore, in this manuscript, we reviewed the characteristics of the available mitochondria-targeted anti-oxidant compounds that could be employed routinely in our nephrology, internal medicine and renal transplant centers. Nevertheless, large clinical trials are needed to provide more definitive information about their use and to assess their overall efficacy or toxicity.
format Online
Article
Text
id pubmed-4660721
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46607212015-11-27 Mitochondria: a new therapeutic target in chronic kidney disease Granata, Simona Dalla Gassa, Alessandra Tomei, Paola Lupo, Antonio Zaza, Gianluigi Nutr Metab (Lond) Review Cellular metabolic changes during chronic kidney disease (CKD) may induce higher production of oxygen radicals that play a significant role in the progression of renal damage and in the onset of important comorbidities. This condition seems to be in part related to dysfunctional mitochondria that cause an increased electron “leakage” from the respiratory chain during oxidative phosphorylation with a consequent generation of reactive oxygen species (ROS). ROS are highly active molecules that may oxidize proteins, lipids and nucleic acids with a consequent damage of cells and tissues. To mitigate this mitochondria-related functional impairment, a variety of agents (including endogenous and food derived antioxidants, natural plants extracts, mitochondria-targeted molecules) combined with conventional therapies could be employed. However, although the anti-oxidant properties of these substances are well known, their use in clinical practice has been only partially investigated. Additionally, for their correct utilization is extremely important to understand their effects, to identify the correct target of intervention and to minimize adverse effects. Therefore, in this manuscript, we reviewed the characteristics of the available mitochondria-targeted anti-oxidant compounds that could be employed routinely in our nephrology, internal medicine and renal transplant centers. Nevertheless, large clinical trials are needed to provide more definitive information about their use and to assess their overall efficacy or toxicity. BioMed Central 2015-11-25 /pmc/articles/PMC4660721/ /pubmed/26612997 http://dx.doi.org/10.1186/s12986-015-0044-z Text en © Granata et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Granata, Simona
Dalla Gassa, Alessandra
Tomei, Paola
Lupo, Antonio
Zaza, Gianluigi
Mitochondria: a new therapeutic target in chronic kidney disease
title Mitochondria: a new therapeutic target in chronic kidney disease
title_full Mitochondria: a new therapeutic target in chronic kidney disease
title_fullStr Mitochondria: a new therapeutic target in chronic kidney disease
title_full_unstemmed Mitochondria: a new therapeutic target in chronic kidney disease
title_short Mitochondria: a new therapeutic target in chronic kidney disease
title_sort mitochondria: a new therapeutic target in chronic kidney disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4660721/
https://www.ncbi.nlm.nih.gov/pubmed/26612997
http://dx.doi.org/10.1186/s12986-015-0044-z
work_keys_str_mv AT granatasimona mitochondriaanewtherapeutictargetinchronickidneydisease
AT dallagassaalessandra mitochondriaanewtherapeutictargetinchronickidneydisease
AT tomeipaola mitochondriaanewtherapeutictargetinchronickidneydisease
AT lupoantonio mitochondriaanewtherapeutictargetinchronickidneydisease
AT zazagianluigi mitochondriaanewtherapeutictargetinchronickidneydisease